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ABSTRACT
Here we describe the application of the in vitro virus
mRNA display method, which involves covalent link-
age of an in vitro-synthesized antibody (phenotype)
to its encoding mRNA (genotype) through puromy-
cin, for in vitro evolution of single-chain Fv (scFv)
antibody fragments. To establish the validity of this
approach to directed antibody evolution, we used
random mutagenesis by error-prone DNA shuffling
and off-rate selection to improve the affinity of
an anti-fluorescein scFv as a model system. After
four rounds of selection of the library of mRNA-
displayed scFv mutants, we obtained six different
sequences encoding affinity-matured mutants with
five consensus mutations. Kinetic analysis of the
mutant scFvs revealed that the off-rates have been
decreased by more than one order of magnitude and
the dissociation constants were improved  30-fold.
The antigen-specificity was not improved by affinity
maturation, but remained similar to that of the wild
type. Although the five consensus mutations of the
high-affinity mutants were scattered over the scFv
sequence, analysis by site-directed mutagenesis
demonstrated that the critical mutations for improv-
ing affinity were the two that lay within the comple-
mentarity determining regions (CDRs). Thus, mRNA
display is expected to be useful for rapid artificial
evolution of high-affinity diagnostic and therapeutic
antibodies by optimizing their CDRs.
INTRODUCTION
Selection technologies, to obtain monoclonal antibodies with
high afﬁnity and speciﬁcity against deﬁned antigens, are
required for the development of diagnostic and therapeutic
antibodies [reviewed in (1–4)], both to improve the detection
limit for diagnostics and to decrease the required dose for
therapeutics. In immunized animals, afﬁnity maturation of
antibodies occurs via repeated stimulation of antigen-speciﬁc
proliferation of B cells and accumulation of point mutations
introduced into the DNA (5–7). Therefore, it has been sug-
gested that the afﬁnity of antibodies can be improved by
mimicking afﬁnity maturation in the laboratory (8,9). For
the in vitro evolution of recombinant antibodies such as
single-chain Fv (scFv) and Fab antibodies, several display
technologies such as phage display (10), yeast surface display
(11), ribosome display (12–15) and DNA display (16) have
been used to link an antibody (phenotype) and its encoding
nucleic acid (genotype).
In this study, we have applied our in vitro virus (IVV)
mRNA display system (17–19) for directed evolution of
a single-chain antibody for the ﬁrst time, although evolution
of antibody mimics (ﬁbronectin type III domains) using
mRNA display has been reported previously (20,21). In
mRNA display, an in vitro-synthesized polypeptide is cova-
lently attached to its encoding mRNA through puromycin
(17,19,22). Unlike phage display and yeast surface display,
mRNA display (as well as ribosome display) is a totally
in vitro system that does not require the transformation of
living cells; thus, very large protein libraries (>10
10 unique
members) can easily be constructed and used for the selection
of antibodies directed against antigens of interest. The cova-
lent bond of the mRNA–protein complex in mRNA display
should be more stable than the protein–ribosome–mRNA
complex used in ribosome display with respect to thermal
or physicochemical stress as a selection pressure. For the pre-
sent study, we used an anti-ﬂuorescein antibody as a model,
because it has been well-characterized both structurally and
kinetically (23,24). Further, laboratory evolution of the anti-
ﬂuorescein antibody was previously performed by yeast
surface display (11) and ribosome display (14); hence, the
antibody is a suitable model for evaluating our new method
in comparison with the previous methods.
MATERIALS AND METHODS
DNA preparation
The oligonucleotide sequences used in this study are listed in
Table 1. A DNA fragment that contains an SP6 promoter, the
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a synthetic gene for anti-ﬂuorescein scFv c12 (14) with a
(Gly4Ser)4 linker, a FLAG-tag and a poly(A) sequence was
constructed as follows. DNA fragments (FluscFv-1 through
FluscFv-9) were assembled by overlap extension PCR with
KOD-dash DNA polymerase (Toyobo) using FluscFv-F and
FluscFv-R primers. The PCR product was cloned into
pCR2.1-TOPO vector (Invitrogen) and the DNA sequence
was conﬁrmed with an ABI PRISM 3100 genetic analyzer
(Applied Biosystems).
Construction of a mutated scFv library
A randomized scFv library was constructed from the wild-
type scFv c12 described above or from the recovered PCR
products after each round of selection. Random point mutage-
nesis and recombination were performed by the combination
of error-prone PCR and PCR-based DNA shufﬂing in a single
PCR tube (26). The PCR was performed with Ex Taq DNA
polymerase (Takara) in the presence of 0.5 mM MnCl2 and
the DNA template (0.2 pmol) using primers W29ATG-F
and FlaA-R (0.3 mM each). The PCR program was as follows:
denaturation at 96 C for 5 min; 80 cycles at 96 C for 30 s and
at 55 C for 5 s; then at 96 C for 30 s, at 58 C for 30 s and at
72 C for 15 min. The PCR product was separated on 1% low-
melting temperature-agarose gel (Sigma) and gel-puriﬁed by
using a Wizard PCR preps DNA puriﬁcation kit (Promega).
To add an SP6 promoter, the puriﬁed DNA (1 pmol) was
re-ampliﬁed by PCR with KOD-plus DNA polymerase
(Toyobo) using SP6-F and FlaA-R primers (10 cycles at
96 C for 30 s; at 58 C for 30 s; and at 72 C for 1 min).
The PCR product was gel-puriﬁed again and used for the
next round of selection.
In vitro transcription and translation
The IVV method was performed as described previously
(27,28) with some modiﬁcations. Approximately 500 ng of
the DNA library was in vitro-transcribed into mRNA using
the RiboMAX large-scale RNA production systems-SP6
(Promega) for 2.5 h at 37 C, then DNase I (Promega) was
added and incubation was continued for a further 0.5 h at
37 C. The mRNA was puriﬁed using an RNeasy mini kit
(Qiagen) and ligated with a polyethyleneglycol (PEG) spacer
[p(dCp)2-T(Cy5)p-PEGp-(dCp)2-puromycin] using T4 RNA
ligase (Takara) at 16 C overnight. The ligation product was
puriﬁed with the RNeasy mini kit and in vitro-translated in
a wheat germ cell-free translation system (Promega) for 1 h
at 25 C. The reaction mixture was centrifuged for 10 min
at 15000 g and the supernatant was used for off-rate
selection.
Off-rate selection
The mRNA-displayed scFv library (2 pmol) was mixed with
antigen (200 nM ﬂuorescein-biotin, 5(6)-(biotinamidohex-
anoylamido)pentylthioureidylﬂuorescein; Sigma) in 1 ml of
blocking solution (DIG wash and block buffer set; Roche)
containing 20 mM EDTA and 100 mg/ml yeast total RNA
(Sigma). The mixture was gently rotated for 1 h at 25 C,
and then added to 50 ml of pre-blocked neutravidin–agarose
beads (Pierce) and rotated for 15 min at 25 C. The beads
were washed six times with 5 ml of PBST [PBS (pH 7.4)
containing 0.2% Tween-20 (Bio-Rad)] at room temperature.
For off-rate selection, 500 ml of PBST containing 1 mM
free ﬂuorescein (Nacarai tesque) and 100 mg/ml yeast total
RNA were added and rotated for an appropriate time
(round 1, 3 h; round 2, 20 h; round 3, 96 h; round 4, 336
h) at 4 C. Again, the beads were washed three times with
500 ml of PBST at room temperature to remove excess anti-
gen. For elution of selected scFv genes, the peptide portion of
the antigen-bound molecules was digested with proteinase K
(Takara) in TE buffer (10 mM Tris–HCl, pH 7.6 and 1 mM
EDTA) for 30 min at 37 C. The eluate was recovered with a

























































Oligonucleotide sequences are indicated in the 50 to 30 direction.
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RNeasy mini kit. The puriﬁed mRNA was reverse-transcribed
with ReverTra Ace reverse-transcriptase (Toyobo) using a
FlaA-R primer for 1 h at 42 C. Subsequently, the RT product
was directly ampliﬁed by PCR with KOD-plus DNA poly-
merase using W29ATG-F and FlaA-R primers (24 cycles at
96 C for 30 s; at 58 C for 30 s; and at 72 C for 1 min).
The PCR product was puriﬁed using a QIAquick PCR puri-
ﬁcation kit (Qiagen).
Cloning and sequencing
The selected DNAs after four rounds were cloned using a
TOPO TA cloning kit (Invitrogen) and sequenced with the
ABI PRISM 3100 genetic analyzer. Subsequently, a signal
sequence (pelB) for periplasmic secretion was added to
each scFv gene by overlap extension PCR with KOD-plus
DNA polymerase using 0.4 mM primers pelB-F and Flag-R
and a 0.02 mM primer pelBleader-F (15 cycles at 96 C for
30 s; at 58 C for 30 s; and at 72 C for 1 min). The PCR prod-
ucts were puriﬁed using the QIAquick PCR puriﬁcation kit
and subcloned using a Champion pET directional TOPO
expression kit (Invitrogen).
Overexpression and purification
The BL21star(DE3)pLysS cells harboring the vector
pET101/D-TOPO for the expression of scFv mutants with a
C-terminal hexahistidine tag were grown in 1.5 liters of TB
medium containing 100 mg/ml ampicillin at 30 C. When
the culture attained an optical density of 0.8 at 600 nm, the
cells were induced by the addition of isopropylthio-b-D-
galactoside (ﬁnal 1 mM). After an additional 3 h incubation,
the cells were harvested by centrifugation and resuspended in
15 ml/g cell of osmotic buffer (30 mM Tris–HCl, pH 7.6,
1 mM EDTA and 0.5 mM sucrose). Again, the cells were
harvested by centrifugation and resuspended in 5 ml/g cell
of ice-cold Milli-Q water. The centrifuged supernatant was
recovered and further centrifuged for 20 min at 15000 g to
separate an insoluble fraction. The supernatant was recovered
as the periplasmic extract for competitive ELISA analysis.
The protein concentration was evaluated by SDS–PAGE
and Western blot analysis using HRP-conjugated anti-FLAG
M2 antibody (Sigma).
For puriﬁcation of proteins, the cells were grown as des-
cribed above, harvested by centrifugation, and resuspended
in 30 ml of TBS containing 100 U of DNase I (Promega),
the EDTA-free protease inhibitor cocktail (Nacarai tesque)
and 20% glycerol. The cells were lysed by sonication using
a Bioruptor UCW-201 (Cosmo Bio) for 50 min at 30 s inter-
vals. The resulting crude extracts were centrifuged for 20 min
at 15000 g and ﬁltered through 0.22 mm PVDF Millex-GV
ﬁlters (Millipore). The clear solution containing the histidine-
tagged scFv protein was puriﬁed by immobilized metal
afﬁnity chromatography (IMAC) using TALON superﬂow
metal afﬁnity resin (Clontech) on an A ¨KTA-FPLC system
(Amersham Biosciences) with running buffer (10 mM
HEPES–NaOH, pH 7.4, 150 mM NaCl and 20 mM imida-
zole) at a ﬂow rate of 0.5 ml/min. The eluate obtained with
a step gradient to 80 mM imidazole in running buffer was
concentrated in a 30 000 MWCO PES Viva-spin 500 (Viva
Science). Subsequently, the monomeric scFv was separated
by size exclusion chromatography using Sephadex G-75
(Amersham Biosciences) with HBS buffer (10 mM
HEPES–NaOH, pH 7.4 and 150 mM NaCl) at a ﬂow rate
of 0.2 ml/min, and then the buffer was changed to HBS-EP
buffer (10 mM HEPES–NaOH, pH 7.4, 150 mM NaCl,
3 mM EDTA and 0.005% Tween-20) by using a MicroSpin
G-25 column (Amersham Biosciences). The concentration
and purity of scFv were conﬁrmed by BCA assay using a
Micro BCA protein assay kit (Pierce) and by CBB staining
of SDS–PAGE gel, respectively.
Competitive ELISA
Streptavidin transparent C8 plates (Nunc) were incubated
with 1 mg/ml ﬂuorescein–biotin (Sigma) in 100 ml of blocking
solution (Roche) per well for 1 h at 25 C, washed with TBST
(TBS, pH 7.4 and 0.2% Tween-20), and blocked with 200 ml
of blocking solution per well before use. Separately, the scFv-
expressed periplasmic extract or wheat germ cell-free trans-
lated product was diluted 5-fold in blocking solution in the
presence and absence of free ﬂuorescein (10–1000 nM),
and incubated for 1 h at 25 C. Then, the protein solution
(100 ml) was transferred into wells on a plate with immobi-
lized antigen and the plate was incubated for 15 min at
25 C. It was immediately washed ﬁve times with TBST
and further incubated for 1 h with HRP-conjugated anti-
FLAG M2 antibody (1:10 000 dilution in TBST; 100 ml per
well). The plate was washed ﬁve times with TBST and then
100 ml of TMB substrate (Nacarai tesque) was added per
well. The reaction was quenched with 1 N H2SO4 (100 ml
per well) and the absorbance at 450 nm (reference wave-
length at 655 nm) was measured. For each clone, the relative
binding activity was calculated as the ratio of the ELISA sig-
nal in the presence of competitor (ﬂuorescein) to that in the
absence of competitor. All the experiments were performed
in duplicate.
For the analysis of antigen-speciﬁcity, competitive ELISA
was performed as described above, except for the use of
various concentrations of ﬂuorescein, Oregon green 488 carb-
oxylic acid (Molecular Probes) or rhodamine 110 (Molecular
Probes) as the competitor.
Surface plasmon resonance (SPR) spectroscopy
All the experiments were performed in duplicate at 25 C with
a Biacore 3000 instrument (Biacore) using HBS-EP buffer.
Fluorescein-conjugated BSA (BSA-FITC; Molecular Probes)
or BSA (Pierce) as a background control was covalently
immobilized onto a CM5 sensor chip (Biacore) by means
of the amine coupling procedure according to the standard
protocol. To prevent the rebinding of analytes to ligands
immobilized on the CM5 sensor chip and to reduce the mass
transport limitation effect, the measurements were performed
under conditions of low ligand amount (450 resonance units)
and high ﬂow rate (60 ml/min). To determine dissociation
constants, ﬁve different concentrations (8–400 nM) of the
puriﬁed scFvs were injected. The injection periods for asso-
ciation and dissociation were 1 and 10 min, respectively.
The surface of the sensor chip was regenerated by pulse injec-
tion of 60 ml of 57 mM HCl (pH 1.2). The binding data were
analyzed with the ‘1:1 binding with mass transfer’ model in
the BIAevaluation software ver. 4.1 (Biacore).
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Strategy for in vitro selection of scFv by mRNA display
The scheme for in vitro selection of anti-ﬂuorescein scFv
using the IVV method is shown in Figure 1. First we con-
structed the template DNA for IVV, containing an SP6 pro-
moter and W enhancer upstream of the anti-ﬂuorescein scFv
gene (VH-linker-VL), and the FLAG-tag and poly(A)
sequence in the downstream region. The scFv region was sub-
jected to random mutagenesis by error-prone PCR (the error
rate was 0.8%; 6–7 nt per scFv gene). The transcribed mRNA
(1.2 · 10
12) molecules were attached to a PEG spacer con-
taining puromycin at the 30 end and in vitro-translated in
10 ml of wheat germ cell-free translation system, resulting
in the covalent bonding of the C-terminus of the full-length
scFv protein (phenotype) with its coding mRNA (genotype)
through the puromycin-PEG spacer. We estimated that the
number of resultant mRNA-displayed scFv molecules in the
initial library was 6 · 10
10 (ligation efﬁciency of mRNA
with the puromycin-PEG spacer and efﬁciency of IVV forma-
tion were 50 and 10%, respectively). The library was cap-
tured on ﬂuorescein-immobilized beads and the mRNA
portion of selected molecules was ampliﬁed by RT–PCR. In
each round of selection, the recovered DNA was further
mutagenized by error-prone DNA shufﬂing (26,29).
Off-rate selection of the randomized scFv library
We applied off-rate selection (10,14) as a selection pressure
for afﬁnity maturation of anti-ﬂuorescein scFv. In off-rate
selection, mRNA-displayed scFvs that bound to ﬂuorescein-
immobilized beads were washed with a large excess of free
ﬂuorescein to prevent the rebinding of antibodies to the
beads. Since the off-rate (koff) depends on the half-life
(t1/2) of the antigen–antibody complex, higher-afﬁnity
binders with low koff can be retained on the beads for a longer
washing time. We set the time periods of off-rate selection so
as to decrease koff about several-fold per round (3, 20, 96 and
336 h). Although mRNA is considered to be a labile mole-
cule, it is stable for at least 2 weeks at low temperature (14).
After four rounds of off-rate selection, the total binding
activity of in vitro-translated products of the library DNA
at each round was analyzed by competitive ELISA. As
shown in Figure 2, the binding activity gradually increased
in successive rounds of selection (Figure 2; 0 nM), whereas
little or no activity was observed in the presence of competi-
tor (Figure 2; 10 nM, 100 nM and 1 mM), indicating the
enrichment of speciﬁc binders with high afﬁnity in the
library.
Competitive ELISA for the second screening
The library DNA from the fourth round of selection was
cloned and sequenced. The rate of amino acid substitutions
was 3.5%. Seventy-seven randomly chosen genes were
subcloned into an Escherichia coli expression vector, their
expression was induced, and the binding activity of scFv
mutants in the periplasmic extracts was analyzed by
ELISA. Clones, whose ELISA signal (OD at 450 nm) was
<0.2, were deﬁned as ELISA-negative and those clones,
whose signal was in the range of 0.2–1.0, were deﬁned as
ELISA-positive. Out of the 77 clones, 45 clones (58%)
were ELISA-positive. In SDS–PAGE analysis, all ELISA-
positive clones exhibited protein expression in the periplasm,
whereas 27 out of 32 ELISA-negative clones showed little or
no expresssion in the periplasm (data not shown). Although
the other ﬁve ELISA-negative clones were expressed in peri-
plasm, three of them showed low ELISA signals (<0.2) and
two had no binding activity (data not shown).
We estimated the afﬁnity of the 45 ELISA-positive clones
by competitive ELISA (Figure 3). The relative binding was
Figure 1. Schematic representation of the in vitro selection of scFv antibodies by the IVV method. Step 1: a DNA library of scFv mutants is in vitro-transcribed
into mRNA. Step 2: the mRNA is enzymatically ligated with puromycin (Pu) through a PEG spacer. Step 3: the ligated product is in vitro-translated by a cell-free
translation system, resulting in covalent bonding of puromycin with the full-length protein at the C-terminus. Step 4: the mRNA-displayed scFv library is
captured on antigen-immobilized beads and unbound molecules are washed away. Step 5: the bound molecules are eluted by protease digestion. Step 6: the
mRNA portion of eluted molecules is reverse-transcribed into cDNA. Step 7: the cDNA is amplified by PCR. Step 8: the DNA can be used for the next round of
selection after mutagenesis or can be analyzed by cloning and sequencing after several rounds of selection.
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free ﬂuorescein as a competitor to that in the absence of
the competitor. The lower relative binding of 37 clones than
that of wild type indicates that these clones have higher
afﬁnity than the wild type. The six highest-afﬁnity clones
with relative binding of <5% and 14 clones with <20%
were classed as Group 1 and Group 2, respectively. The
amino acid changes are listed in Table 2. All six Group 1
mutants with the highest afﬁnity contain ﬁve consensus muta-
tions, W47C in FR H2, D101N in CDR H3, S15F in the lin-
ker, V21I in FR L1 and H94Y in CDR L3 (Table 2, boldface),
whereas a majority of the 14 Group 2 mutants with moderate
afﬁnity contain four consensus mutations, A68V in FR H3,
G96D in CDR H3, R18M in FR L1 and H94Y in CDR L3.
Notably, the mutation H94Y in CDR L3 was contained in
both Group 1 and Group 2 mutants. It is likely that the advan-
tageous mutations were accumulated among the afﬁnity-
matured scFv genes during the repetition of DNA shufﬂing
and off-rate selection in the selection cycles.
Characterization of the affinity-matured mutants
The binding afﬁnities of puriﬁed scFvs (ﬁve Group 1 mutants
and a Group 2 mutant, 2-10) were measured by SPR spec-
troscopy (Table 3 and Figure 4). Although the on-rates of
the mutants were similar to that of the wild type, the off-
rates were decreased by more than one order of magnitude,
suggesting that the application of selection pressure by off-
rate selection had been successful. The dissociation constants
of Group 1 mutants were improved by  30-fold, which is
comparable with that obtained by ribosome display (14),
probably because the selection conditions were similar to
each other.
Next, we examined the antigen-speciﬁcity of the afﬁnity-
matured mutants by competitive ELISA. Two ﬂuorescein
analogs, Oregon green 488 and rhodamine green, as well as
Figure 2. Competitive ELISA for monitoring the fraction of the mutant scFv
library that bound to fluorescein at each round of selection. The wheat germ
cell-free translated products containing mutant scFv libraries were pre-
incubated with a competitor (0–1000 nM free fluorescein) and allowed to
bind to fluorescein-immobilized plates. After washing of the plates,
remaining scFvs were detected by HRP-conjugated anti-FLAG M2 antibody
and TMB substrate with absorbance measurements at 450 nm (reference at
655 nm). All measurements were performed in duplicate.
Figure 3. Competitive ELISA for estimating the affinities of 45 selected clones after the fourth round of selection. The periplasmic extracts for wild type and
mutant scFv clones were pre-incubated in the presence or absence of 10 nM fluorescein, and then allowed to bind to fluorescein-immobilized plates. After the
plates were washed, remaining scFvs were detected by HRP-conjugated anti-FLAG M2 antibody and TMB substrate with absorbance measurements at 450 nm
(reference at 655 nm). The relative binding indicates the ratio of the ELISA signal in the presence of the competitor to that in the absence of the competitor; thus,
lower relative binding of clones compared with the wild-type scFv (WT; filled bar) indicates that these clones have higher affinity than the wild type. All the
measurements were performed in duplicate.
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ity of Group 1 mutant 2-12 (Figure 5C) was higher than that
of wild type (Figure 5B), not only for ﬂuorescein but also for
the two ﬂuorescein analogs, with an almost identical ratios
of increase. Similar results were obtained for the other ﬁve
Group 1 mutants (data not shown). The results suggest that
the speciﬁcity of the afﬁnity-matured mutants was not
altered, but remained similar to that of the wild type.
To determine the most important mutations for afﬁnity
improvement, we ﬁrst constructed an scFv mutant that con-
tains only the ﬁve consensus mutations in Group 1 mutants
(named CM5). As shown in Figure 6A (ﬁlled triangles), the
activity of the CM5 mutant was similar to that of Group 1
mutants (such as 2-12 shown in Figure 5C, ﬁlled squares),
indicating that only the ﬁve mutations in Group 1 contribute
signiﬁcantly to the increased afﬁnity. Subsequently, we con-
structed and examined ﬁve scFv mutants, each with a single
amino acid mutation, W47C, D101N, S15F, V21I or H94Y.
Three mutations, W47C and V21I in the framework
and S15F in the linker, did not inﬂuence binding activity
(Figure 6B), whereas two, D101N or H94Y in the CDR,
resulted in intermediate binding activity between CM5
and wild type (Figure 6C). Moreover, the double mutant
containing both D101N and H94Y showed binding activity
similar to that of CM5 (Figure 6C, ﬁlled diamonds). These
results clearly demonstrated that the critical mutations for
improving afﬁnity are D101N and H94Y in CDR3 of VH
and VL, respectively. This result is consistent with the previ-
ous ﬁndings in laboratory evolution of high-afﬁnity scFv
mutants with CDR mutations (11,14). The locations of the
CDR mutations on the three-dimensional structure were
very close to the ﬂuorescein site (14). It has been argued
that the mutation H94Y in VL directly affects the interaction
Table 2. Mutations in scFv fragments selected by the IVV method
Clone VH VL Linker
Group 1
7-753 W47C, D101N V21I, S76T, H94Y S15F
2-12 W47C, A68T, K73Q, D101N V21I, H94Y S15F
7-308 W47C, D101N V21I, A51V, H94Y S15F
1-13 K19R, S21T, W47C, S74N, S76G, S82bG, E85D, D101N, Y102N, S112F V21I, S80T, H94Y, E105K G12S, S15F
3-23 K19R, W47C, S74N, Q81H, S82bG, D101N, Y102N V21I, S80T, H94Y G12S, S15F
7-464 W47C, K62N, K73I, D101N V21I, Q38H, H94Y S15F
Group 2
6-77 G96D M11L, P59S, H94Y G19D
7-007 A68V, G96D, S112P R18M, H94Y
3-6 A68V, G96D R18M, H94Y S5L
2-23 A68V, G96D R18M, Y53H, H94Y
5-9 A68V, Q81R, D101N V21I, D30H S15F
7-303 A68V, G96D T13I, R18M, D70S, H94Y, L104M
5-35 A68V, G96D R18M, P59H, S67Y, H94Y
7-665 A68V, G96D R18M, K24R, L83S, H94Y S20I
2-10 A68V, G96D R18M, H94Y
7-656 S30T, M80L, Y99H T22I, A84T, H94Y, K103M S15P
1-7 N58I, G96D I2V, V21I, N32K, Y53C, D60G
4-14 Q3R, W47C, S76R, M80L, Y99N H94Y
7-283 W47C, S76R, M80L, Y99N G68R, H94Y
7-822 K64N, A68V, G96D R18M, H94Y G11C
Amino acid mutations of the VH,V L and linker regions of selected mutants. Residue numbering is according to Kabat et al. (32). The original sequence of the wild
type is shown in (14). Group 1 and Group 2 indicate 6 clones with high activity and 14 clones with moderate activity, respectively (see also Figure 3). Boldface
residues indicate five consensus mutations.
Table 3. Kinetic parameters of selected clones
Clone kon (M
 1 s
 1 · 10
5) koff (s
 1 · 10
 4) KD (nM) t1/2 (min)
Wild type 1.0 ± 0.05* 33 ± 0.62 32 3.5
2-12 1.9 ± 0.02 1.8 ± 0.007 0.95 64
3-23 3.7 ± 0.06 3.3 ± 0.17 0.88 35
7-308 3.6 ± 0.02 3.6 ± 0.01 0.99 33
7-464 1.2 ± 0.002 1.7 ± 0.009 1.4 70
7-753 1.1 ± 0.02 1.8 ± 0.008 1.7 63
2-10 0.26 ± 0.002 2.0 ± 0.18 7.5 59
*Mean ± SEM.
Figure 4. Kinetic distribution plot. The kinetic parameters of purified scFvs
were determined by SPR spectroscopy (see Materials and Methods and
Table 3). The wild type (open circle); Group 1 mutants 2-12 (filled circle),
7-753 (open square), 3-23 (filled square), 7-308 (open triangle) and 7-464
(filled triangle); and Group 2 mutant 2-10 (filled diamond). The dissociation
constants (Kd ¼ koff/kon) are represented as gray lines (0.1–10 nM). Group
1 mutants with highest affinity were clustered in the upper right-hand corner
of the plot.
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tions D101G, D101A and D101S in VH break the salt bridge
between D101 and R94 in VH and increase the ﬂexibility of
CDR H3 (14). Our results suggest that the mutation D101N in
VH also affects the afﬁnity via a mechanism similar to that of
the mutations D101G, D101A and D101S. The framework
mutations W47C in VH and V21I in VL, as well as the linker
mutation S15F, may be neutral mutations ﬁxed in an early
round of selection by random genetic drift.
In summary, completely in vitro evolution of a single-
chain antibody by using the IVV mRNA display method
was accomplished for the ﬁrst time. By means of the com-
bination of off-rate selection and DNA shufﬂing, the afﬁnity
of scFv mutants was improved  30-fold without affecting the
speciﬁcity. The critical mutations D101N in VH and H94Y in
VL located within the CDRs are similar to those previously
found by ribosome display (14). Although both mRNA
display and ribosome display are totally in vitro selection
systems that allow the selection of antibodies against novel
Figure 5. Competitive ELISA for estimating the antigen-specificity of the
affinity-matured mutants. (A) The structures of fluorescein, Oregon green 488
and rhodamine green. For immobilization on the ELISA plates, biotin is
attached to the benzene moiety of fluorescein; thus, differences of the
xanthene moiety would be critical for scFv binding. The periplasmic extracts
of the wild type (B) and a typical mutant 2-12 (C) were pre-incubated in the
presence of various concentrations of fluorescein (filled squares), Oregon
green 488 (open circles) or rhodamine green (filled triangles). The other five
mutants in Group 1 gave similar curves. For experimental details, see the
legend of Figure 3 and Materials and Methods.
Figure 6. Competitive ELISA for analysis of the contributions of the five
consensus mutations in Group 1 mutants. The periplasmic extracts of the
wild-type and mutant scFvs were pre-incubated in the presence of various
concentrations of fluorescein. For experimental details, see the legend of
Figure 3 and Materials and Methods. (A) The wild type (open circles, dashed
line) and the mutant CM5 (filled triangles, dotted line). (B) The single
mutants W47C (filled squares), V21I (open diamonds) and S15F (open
triangles); the wild type (a dashed line) and CM5 (a dotted line). (C) The
single mutants D101N (filled circles) and H94Y (open squares); the double
mutant D101N/H94Y (filled diamonds); the wild type (dashed line) and CM5
(dotted line).
PAGE 7 OF 8 Nucleic Acids Research, 2006, Vol. 34, No. 19 e127antigens, including toxic molecules, from a huge library, only
fewer applications of mRNA display than that of ribosome
display have been reported so far (30). Our results demon-
strate that mRNA display can be expected to be useful for
rapid and efﬁcient evolution of high-afﬁnity antibodies for
diagnostic and therapeutic applications by optimizing the
CDRs. Furthermore, in comparison with ribosome display,
the use of a covalent bond in mRNA display should allow
in vitro selection of antibodies with high stability at a higher
temperature or in the presence of denaturants of ribosomes, as
well as the selection of metal-dependent antibodies (31) in
the presence and absence of EDTA. We believe that this
method should also be applicable to in vitro selection of
scFv antibodies directed against various antigens from naive
or synthetic scFv libraries.
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